tradingkey.logo

Arcus Biosciences Inc <RCUS.N> expected to post a loss of $1.25 a share - Earnings Preview

ReutersFeb 21, 2025 10:24 PM
  • Arcus Biosciences Inc RCUS.N, RCUS.K is expected to show a fall in quarterly revenue when it reports results on February 25 for the period ending December 31 2024

  • The Hayward California-based company is expected to report a 6.8% decrease in revenue to $28.9 million from $31 million a year ago, according to the mean estimate from 10 analysts, based on LSEG data.The company's guidance on November 6 2024, for the period ended December 31, was for revenue of $30.000 million.

  • ​LSEG's mean analyst estimate for Arcus Biosciences Inc is for a loss of $1.25 per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Arcus Biosciences Inc is $29.00​, above​ its last closing price of $11.07. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Sep. 30 2024

-1.03

-1.06

-1.00

Beat

5.9

Jun. 30 2024

-1.12

-1.10

-1.02

Beat

7.1

Mar. 31 2024

-1.02

-0.95

-0.05

Beat

94.7​

Dec. 31 2023

-1.00

-1.02

-1.08

Missed

-5.5

​​Sep. 30 2023

-1.12

-1.13

-0.94

Beat

16.7

Jun. 30 2023

-1.09

-1.10

-1.04

Beat

5.3​

Mar. 31 2023

-1.17

-1.16

-1.09

Beat

6.3

Dec. 31 2022

-1.02

-1.07

-0.93

Beat

12.8

This summary was machine generated February 21 at 22:24 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI